Home » Stocks » AGE

AgeX Therapeutics, Inc. (AGE)

Stock Price: $1.90 USD -0.01 (-0.26%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 71.42M
Revenue (ttm) 1.91M
Net Income (ttm) -11.13M
Shares Out 37.68M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $1.90
Previous Close $1.90
Change ($) -0.01
Change (%) -0.26%
Day's Open 1.98
Day's Range 1.88 - 1.98
Day's Volume 310,990
52-Week Range 0.68 - 2.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 weeks ago

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual...

Business Wire - 2 months ago

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to incre...

Business Wire - 2 months ago

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat hum...

InvestorPlace - 3 months ago

AgeX Therapeutics (AGE) stock is soaring higher on Thursday following news of that Juvenescence has a 50% stake in the company. The post AgeX Therapeutics News: Why AGE Stock Is Skyrocketing 1...

Business Wire - 4 months ago

ALAMEDA, Calif. & CARLSBAD, Calif.

Other stocks mentioned: LCTX
Seeking Alpha - 8 months ago

AgeX Therapeutics: Revolutionary Potential But Extremely Early

About AGE

AgeX Therapeutics, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therap... [Read more...]

Industry
Biotechnology
IPO Date
Nov 29, 2018
CEO
Michael West
Employees
17
Stock Exchange
NYSEAMERICAN
Ticker Symbol
AGE
Full Company Profile

Financial Performance

In 2019, AGE's revenue was $1.73 million, an increase of 23.78% compared to the previous year's $1.40 million. Losses were -$12.15 million, 62.0% more than in 2018.

Financial Statements